US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
BeOne Medicines Ltd. - American Depositary Shares
(NQ:
ONC
)
361.65
+3.58 (+1.00%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BeOne Medicines Ltd. - American Depositary Shares
< Previous
1
2
3
4
5
Next >
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
September 01, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
August 31, 2026
From
BeOne Medicines, Ltd.
Via
Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
August 31, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
August 25, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
August 18, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
BRUKINSA revenue surged 31% while management raised full-year guidance by $300 million.
Via
The Motley Fool
Topics
Earnings
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
August 10, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Q2 Earnings Call Highlights
↗
August 05, 2026
BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued...
Via
MarketBeat
Topics
Earnings
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
August 05, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
July 23, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position
↗
July 22, 2026
Executed under pre-established trading plan, this sale reduces the chief executive's direct holdings by just 2%.
Via
The Motley Fool
Topics
Regulatory Compliance
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
July 17, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
June 30, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
June 12, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
June 11, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
↗
June 02, 2026
BeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company...
Via
MarketBeat
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
June 01, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
May 29, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
May 27, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
May 21, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
May 20, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
↗
May 16, 2026
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.
Via
The Motley Fool
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
↗
May 14, 2026
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
↗
May 14, 2026
Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.
Via
The Motley Fool
Topics
Initial Public Offering
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%
↗
May 14, 2026
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types.
Via
The Motley Fool
Topics
Regulatory Compliance
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
May 13, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
May 06, 2026
From
BeOne Medicines Ltd
Via
Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
April 29, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
April 22, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
